Comparable stake leader
Alumni Capital LP
SEC ownership of RedHill Biopharma Ltd.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001553846.
Disclosed value leader
Alumni Capital LP
Comparable rows
2/17
Latest evidence
01 Oct 2026
- Public ticker
- RDHL on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Alumni Capital LP
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
2 of 17
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Alumni Capital LP
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
01 Oct 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001553846
- Issuer location
- Tel Aviv, Israel
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of RedHill Biopharma Ltd. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Alumni Capital LP
Disclosed value leader
Alumni Capital LP
Comparable rows
2/17
Latest evidence
01 Oct 2026
13D/G
13F
3/4/5
Lead comparable stake: 10%
15 rows are not safely comparable across share classes.
13D/G row: Alumni Capital LP
Showing 1-8 of 17 holder rows.
Quick read
Alumni Capital LP leads the comparable SEC ownership view at 10%.
2 of 17 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Alumni Capital LP's linked filing trail.
Comparable ownership
Top 2
Alumni Capital LP
10%
YA II PN, Ltd.
9.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 17 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Alumni Capital LP |
13D/G
|
10%
Reported 13D/G
· 20 Jun 2025
|
$801,687
369,373 shares
|
$0 | 20 Jun 2025 |
| YA II PN, Ltd. |
13D/G
|
9.9%
Reported 13D/G
· 19 Dec 2025
|
$559,595
508,723 shares
|
$0 | 19 Dec 2025 |
| GAGNON SECURITIES LLC |
13F
Company
|
—
denominator unverified
|
$42,434
88,405 shares
|
— | 30 Sep 2026 |
| MORGAN STANLEY |
13F
Company
|
—
denominator unverified
|
$147
306 shares
|
— | 30 Sep 2026 |
| BNP PARIBAS FINANCIAL MARKETS |
13F
Company
|
—
denominator unverified
|
$144
300 shares
|
— | 30 Sep 2026 |
| GAMMA Investing LLC |
13F
Company
|
—
denominator unverified
|
$138
287 shares
|
— | 30 Sep 2026 |
| SBI Securities Co., Ltd. |
13F
Company
|
—
denominator unverified
|
$10
21 shares
|
— | 30 Sep 2026 |
| Dror Ben-Asher |
3/4/5
Chief Executive Officer, Director
|
—
denominator unverified
|
—
441,350,000 shares
|
— | 18 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
No eligible buy or sell activity is available for this window. No eligible Buy or Sell transactions are available in this dataset since 15 Nov 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-10 of 10 reporting-owner rows connected to RedHill Biopharma Ltd.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
10
Largest Forms 3/4/5 holder
Dror Ben-Asher
Net 12M change
$0
Latest report
01 Oct 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Dror Ben-Asher | Chief Executive Officer, Director | Mixed | 18 Mar 2026 | |||
| Shmuel Cabilly | Director | Mixed | 18 Mar 2026 | |||
| Adi Frish | Chief Corp & BD Officer | Mixed | 18 Mar 2026 | |||
| Guy Joel Goldberg | Chief Business Officer | Mixed | 18 Mar 2026 | |||
| Razi Ingber | Chief Financial Officer | Mixed | 18 Mar 2026 | |||
| Roni Mamluk | Director | Mixed | 18 Mar 2026 | |||
| Kenneth Reed | Director | Mixed | 18 Mar 2026 | |||
| Rick D. Scruggs | Chief Commercial Officer, Director | Mixed | 18 Mar 2026 | |||
| Ofer Tsimchi | Director | Mixed | 18 Mar 2026 | |||
| Gilead Raday | Chief Operating Officer | Mixed | 01 Oct 2026 |
Recent insider transactions for RedHill Biopharma Ltd.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Raday | RDHL | Ordinary Shares | Sale | -7.48% | -14,310,000 | 176,910,000 | 01 Oct 2026 | Direct | ||
| Gilead Raday | RDHL | American Depository Shares | Options Exercise | 26.5% | 27,560,000 | 131,690,000 | 01 Oct 2026 | Direct | ||
| Gilead Raday | RDHL | Ordinary Shares | Sale | -6.07% | -14,130,000 | 218,780,000 | 10 Jul 2026 | Direct | ||
| Gilead Raday | RDHL | American Depositary Shares | Options Exercise | 37% | 28,150,000 | 104,130,000 | 10 Jul 2026 | Direct | ||
| Gilead Raday | RDHL | Ordinary Shares | Sale | -5.69% | -15,740,000 | 261,060,000 | 06 Apr 2026 | Direct | ||
| Gilead Raday | RDHL | American Depositary Shares | Options Exercise | 67.8% | 30,780,000 | 76,150,000 | 06 Apr 2026 | Direct |
* marks a reported price that did not pass the local price check.